2024/04/28 更新

写真a

トオダ エツコ
遠田 悦子
Toda Etsuko
所属
医学部 病理学(解析人体病理学) 教授
職名
教授
プロフィール

はじまりは経口免疫寛容の研究でした。食物抗原に対する免疫応答の制御は全身に及んでいることを知り、からだ全体を守る免疫細胞の遊走を制御するしくみに興味をもちました。白血球遊走因子ケモカインの研究に足を踏み入れ、以来、ケモカイン受容体シグナル制御分子の機能解析を通じて、免疫細胞、特にマクロファージの動きと活性化をうまく調節することで副作用なく疾患を治療・予防することを目指しています。

研究キーワード

  • マクロファージ

  • ケモカイン

  • ケモカイン受容体

  • FROUNT

  • 細胞遊走

研究分野

  • ライフサイエンス / 免疫学  / 免疫細胞生物学

  • ライフサイエンス / 実験病理学

学歴

  • 東京大学大学院医学系研究科 社会医学専攻(博士課程)

    2003年4月 - 2007年3月

      詳細を見る

  • 東京大学大学院農学生命科学研究科 応用生命化学専攻(修士課程)

    2001年4月 - 2003年3月

      詳細を見る

  • 東京大学

    1997年4月 - 2001年3月

      詳細を見る

  • 東京大学 農学部

    1999年4月 - 2001年3月

      詳細を見る

  • 茨城県立土浦第一高等学校

    1994年4月 - 1997年3月

      詳細を見る

経歴

  • 日本医科大学   研究部共同研究施設 形態解析研究室   教授

    2024年4月 - 現在

      詳細を見る

  • 東京理科大学   生命医科学研究所   客員教授

    2024年3月 - 現在

      詳細を見る

  • 日本医科大学   解析人体病理学

    2023年11月 - 現在

      詳細を見る

  • 日本医科大学 解析人体病理学 講師

    2023年4月 - 2023年11月

      詳細を見る

  • 東京理科大学   客員研究員

    2019年5月 - 2024年3月

      詳細を見る

  • 日本医科大学 解析人体病理学 助教

    2019年5月 - 2023年3月

      詳細を見る

  • 東京理科大学   炎症・免疫難病制御部門   助教

    2018年4月 - 2019年4月

      詳細を見る

  • 東京大学   特任助教

    2014年4月 - 2018年3月

      詳細を見る

  • 東京大学   特任研究員

    2009年4月 - 2014年3月

      詳細を見る

  • 東京大学   産学官連携研究員

    2007年10月 - 2009年3月

      詳細を見る

▼全件表示

所属学協会

▼全件表示

論文

  • Targeting FROUNT with disulfiram suppresses macrophage accumulation and its tumor-promoting properties. 査読 国際誌

    Yuya Terashima, Etsuko Toda, Meiji Itakura, Mikiya Otsuji, Sosuke Yoshinaga, Kazuhiro Okumura, Francis H W Shand, Yoshihiro Komohara, Mitsuhiro Takeda, Kana Kokubo, Ming-Chen Chen, Sana Yokoi, Hirofumi Rokutan, Yutaka Kofuku, Koji Ohnishi, Miki Ohira, Toshihiko Iizasa, Hirofumi Nakano, Takayoshi Okabe, Hirotatsu Kojima, Akira Shimizu, Shiro Kanegasaki, Ming-Rong Zhang, Ichio Shimada, Hiroki Nagase, Hiroaki Terasawa, Kouji Matsushima

    Nature communications   11 ( 1 )   609 - 609   2020年1月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Tumor-associated macrophages affect tumor progression and resistance to immune checkpoint therapy. Here, we identify the chemokine signal regulator FROUNT as a target to control tumor-associated macrophages. The low level FROUNT expression in patients with cancer correlates with better clinical outcomes. Frount-deficiency markedly reduces tumor progression and decreases macrophage tumor-promoting activity. FROUNT is highly expressed in macrophages, and its myeloid-specific deletion impairs tumor growth. Further, the anti-alcoholism drug disulfiram (DSF) acts as a potent inhibitor of FROUNT. DSF interferes with FROUNT-chemokine receptor interactions via direct binding to a specific site of the chemokine receptor-binding domain of FROUNT, leading to inhibition of macrophage responses. DSF monotherapy reduces tumor progression and decreases macrophage tumor-promoting activity, as seen in the case of Frount-deficiency. Moreover, co-treatment with DSF and an immune checkpoint antibody synergistically inhibits tumor growth. Thus, inhibition of FROUNT by DSF represents a promising strategy for macrophage-targeted cancer therapy.

    DOI: 10.1038/s41467-020-14338-5

    PubMed

    researchmap

  • Disulfiram treatment suppresses antibody-producing reactions by inhibiting macrophage activation and B cell pyrimidine metabolism 査読

    Weili Chen, Etsuko Toda, Kazuhiro Takeuchi, Yurika Sawa, Kyoko Wakamatsu, Naomi Kuwahara, Arimi Ishikawa, Yuri Igarashi, Mika Terasaki, Shinobu Kunugi, Yasuhiro Terasaki, Kazuhiko Yamada, Yuya Terashima, Akira Shimizu

    Communications Biology   2024年4月

     詳細を見る

    担当区分:責任著者   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/s42003-024-06183-9

    researchmap

  • Predominant CD8+ cell infiltration and low accumulation of regulatory T cells in immune checkpoint inhibitor-induced tubulointerstitial nephritis. 国際誌

    Kenta Tominaga, Etsuko Toda, Kazuhiro Takeuchi, Shoichiro Takakuma, Emi Sakamoto, Hideaki Kuno, Yusuke Kajimoto, Yasuhiro Terasaki, Shinobu Kunugi, Akiko Mii, Yukinao Sakai, Mika Terasaki, Akira Shimizu

    Pathology international   2024年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Immune checkpoint inhibitors (ICIs) can provide survival benefits to cancer patients; however, they sometimes result in the development of renal immune-related adverse events (irAEs). Tubulointerstitial nephritis (TIN) is the most representative pathological feature of renal irAEs. However, the clinicopathological entity and underlying pathogenesis of ICI-induced TIN are unclear. Therefore, we compared the clinical and histological features of this condition with those of non-ICI drug-induced TIN. Age and C-reactive protein levels were significantly higher in ICI-induced TIN, but there were no significant differences in renal function. Immunophenotyping of ICI-induced TIN showed massive T cell and macrophage infiltration with fewer B cells, plasma cells, neutrophils, and eosinophils. Compared with those in non-ICI drug-induced TIN, CD4+ cell numbers were significantly lower in ICI-induced TIN but CD8+ cell numbers were not significantly different. However, CD8/CD3 and CD8/CD4 ratios were higher in ICI-induced TIN. Moreover, CD25+ and FOXP3+ cells, namely regulatory T cells, were less abundant in ICI-induced TIN. In conclusion, T cell, B cell, plasma cell, neutrophil, and eosinophil numbers proved useful for differentiating ICI-induced and non-ICI drug-induced TIN. Furthermore, the predominant distribution of CD8+ cells and low accumulation of regulatory T cells might be associated with ICI-induced TIN development.

    DOI: 10.1111/pin.13428

    PubMed

    researchmap

  • From Microscope to AI: Developing an Integrated Diagnostic System for Endometrial Cytology

    Mika Terasaki, Shun Tanaka, Ichito Shimokawa, Etsuko Toda, Shoichiro Takakuma, Ryo Tabata, Kensuke Sakae, Yusuke Kajimoto, Shinobu Kunugi, Akira Shimizu, Yasuhiro Terasaki

    2024年4月

     詳細を見る

    出版者・発行元:Research Square Platform LLC  

    Abstract

    Objective To explore the integration of artificial intelligence (AI)-assisted diagnostics into a cytology workflow, focusing on real-time detection of abnormal cell clusters in endometrial cytology without relying on whole-slide imaging (WSI), utilizing a YOLOv5x-based model.Methods We employed the YOLOv5x object detection model pretrained on the COCO dataset because of its high-speed and accurate detection capabilities. This study involved real-time direct detection of abnormal cell clusters using a CCD camera attached to a microscope, with the aim of enhancing diagnostic efficiency and accuracy in endometrial cytology. The model was further refined through transfer learning using actual cytology case images, emphasizing the need for a delicate balance between technological advancement and clinical integration.Results The integration of our AI model into the diagnostic workflow significantly reduced the time required for diagnosis compared to traditional methods, as demonstrated by the performance metrics that matched or exceeded those of pathologists. This breakthrough underscores the potential of AI to improve diagnostic workflows, particularly in settings where resources or pathology services are limited.Conclusion This study presents the first instance of an AI-assisted system for endometrial cytology that operates in real time under a microscope, negating the need for WSI. Our findings highlight the feasibility of embedding AI directly into existing clinical practices, offering significant time savings and potentially matching the diagnostic accuracy of specialists. The successful integration of this technology is a critical step forward in the application of AI in the medical field, paving the way for broader adoption and further research into user-friendly AI applications in pathology diagnostics.

    DOI: 10.21203/rs.3.rs-4205271/v1

    researchmap

    その他リンク: https://www.researchsquare.com/article/rs-4205271/v1.html

  • Disulfiram, an Anti-alcoholic Drug, Targets Macrophages and Attenuates Acute Rejection in Rat Lung Allografts. 国際誌

    Nobuyuki Yoshiyasu, Rei Matsuki, Masaaki Sato, Hirokazu Urushiyama, Etsuko Toda, Yasuhiro Terasaki, Masaki Suzuki, Aya Shinozaki-Ushiku, Yuya Terashima, Jun Nakajima

    Transplant international : official journal of the European Society for Organ Transplantation   37   12556 - 12556   2024年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Macrophages contribute to post-transplant lung rejection. Disulfiram (DSF), an anti-alcoholic drug, has an anti-inflammatory effect and regulates macrophage chemotactic activity. Here, we investigated DSF efficacy in suppressing acute rejection post-lung transplantation. Male Lewis rats (280-300 g) received orthotopic left lung transplants from Fisher 344 rats (minor histocompatibility antigen-mismatched transplantation). DSF (0.75 mg/h) monotherapy or co-solvent only (50% hydroxypropyl-β-cyclodextrin) as control was subcutaneously administered for 7 days (n = 10/group). No post-transplant immunosuppressant was administered. Grades of acute rejection, infiltration of immune cells positive for CD68, CD3, or CD79a, and gene expression of monocyte chemoattractant protein and pro-inflammatory cytokines in the grafts were assessed 7 days post-transplantation. The DSF-treated group had significantly milder lymphocytic bronchiolitis than the control group. The infiltration levels of CD68+ or CD3+ cells to the peribronchial area were significantly lower in the DSF than in the control groups. The normalized expression of chemokine ligand 2 and interleukin-6 mRNA in allografts was lower in the DSF than in the control groups. Validation assay revealed interleukin-6 expression to be significantly lower in the DSF than in the control groups. DSF can alleviate acute rejection post-lung transplantation by reducing macrophage accumulation around peripheral bronchi and suppressing pro-inflammatory cytokine expression.

    DOI: 10.3389/ti.2024.12556

    PubMed

    researchmap

  • A Novel Multi-Observation System to Study the Effects of Anterior Ocular Inflammation in Zinn's Zonule Using One Specimen. 査読 国際誌

    Akira Takahashi, Takeshi Arima, Etsuko Toda, Shinichiro Kobayakawa, Akira Shimizu, Hiroshi Takahashi

    International journal of molecular sciences   24 ( 7 )   2023年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Zinn's zonule is a fragile and thin tissue, and little is known about its pathogenesis. The aim of this study was to develop an experimental setup for a comprehensive analysis of Zinn's zonule. Rats were divided into two groups: a control group (n = 4) and an alkali injury group (n = 4). Seven days after injury, the eyes were enucleated, the anterior eye was dissected and embedded in gelatin, and macroscopic observations were made. The gelatin specimens were then embedded in paraffin and observed in detail by low-vacuum scanning electron microscopy, immunofluorescence, and quantitative reverse transcription polymerase chain reaction (RT-qPCR). The results show qualitative changes in Zinn's zonules in both macroscopic and microscopic observations. In addition, macrophage infiltration and increased matrix metalloproteinase 2 (MMP2) expression were observed in the injured group, consistent with the RT-qPCR results. The experimental system in this study allowed us to capture the morphological and molecular biological changes of Zinn's zonule and to gain insight into its pathogenesis. In conclusion, this study presents a new experimental setup for the comprehensive analysis of the rat Zinn's zonule. The results suggest that this system can be used in the future to study and analyze a variety of paraffin-embedded tissues and specimens.

    DOI: 10.3390/ijms24076254

    PubMed

    researchmap

  • Immune checkpoint inhibitors associated granulomatous small vessel vasculitis accompanied with tubulointerstitial nephritis: a case report. 査読 国際誌

    Kenta Tominaga, Kazuhiro Takeuchi, Shoichiro Takakuma, Emi Sakamoto, Saeko Hatanaka, Yusuke Kajimoto, Etsuko Toda, Yasuhiro Terasaki, Shinobu Kunugi, Mika Terasaki, Akira Shimizu

    BMC nephrology   24 ( 1 )   48 - 48   2023年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Immune checkpoint inhibitors (ICIs) have provided significant benefits in cancer treatment, but they could develop immune-related adverse events (irAE). ICI-associated renal adverse effects are rare and tubulointerstitial nephritis (TIN) is the most common in the renal irAE. However, only a few case reports of renal vasculitis associated with ICI have been reported. In addition, the characteristics of infiltrating inflammatory cells of ICI-associated TIN and renal vasculitis have been uncertain. CASE PRESENTATION: A 65-year-old man received immune checkpoint inhibitors (ICIs), anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) and anti-PD-1 (programmed cell death 1) antibodies for aggravated metastatic malignant melanoma. About 1 week after the second administration of nivolumab and ipilimumab, acute kidney injury developed. A renal biopsy was performed that showed TIN and non-necrotizing granulomatous vasculitis in interlobular arteries. Massive CD3+ T cells and CD163+ macrophages infiltrated both tubulointerstitium and interlobular arteries. Many infiltrating cells tested positive for Ki-67 and PD-1 ligand (PD-L1), but negative for PD-1. In CD3+ T cells, CD8+ T cells were predominantly infiltrated, and these cells were positive for Granzyme B (GrB) and cytotoxic granule TIA-1, but negative for CD25, indicating antigen-independent activated CD8+ T cells. Infiltration of CD4+ T cells was noted without obvious CD4+ CD25+ regulatory T (Treg) cells. His renal dysfunction recovered within 2 months of treatment with prednisolone in addition to discontinuation of nivolumab and ipilimumab. CONCLUSIONS: We herein reported a case of ICI-related TIN and renal granulomatous vasculitis with infiltration of massive antigen-independent activated CD8+ T cells and CD163+ macrophages, and none or few CD4+ CD25+ Treg cells. These infiltrating cells might be a characteristic of the development of renal irAE.

    DOI: 10.1186/s12882-023-03091-8

    PubMed

    researchmap

  • Disulfiram Ophthalmic Solution Inhibited Macrophage Infiltration by Suppressing Macrophage Pseudopodia Formation in a Rat Corneal Alkali Burn Model. 査読 国際誌

    Toyo Ikebukuro, Takeshi Arima, Momoko Kasamatsu, Yuji Nakano, Yutaro Tobita, Masaaki Uchiyama, Yuya Terashima, Etsuko Toda, Akira Shimizu, Hiroshi Takahashi

    International journal of molecular sciences   24 ( 1 )   2023年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    FROUNT is an intracellular protein that promotes pseudopodia formation by binding to the chemokine receptors CCR2 and CCR5 on macrophages. Recently, disulfiram (DSF), a drug treatment for alcoholism, was found to have FROUNT inhibitory activity. In this study, we investigated the effect of DSF eye drops in a rat corneal alkali burn model. After alkali burn, 0.5% DSF eye drops (DSF group) and vehicle eye drops (Vehicle group) were administered twice daily. Immunohistochemical observations and real-time reverse transcription-polymerase chain reaction (RT-PCR) analyses were performed at 6 h and 1, 4, and 7 days after alkali burn. Results showed a significant decrease in macrophage accumulation in the cornea in the DSF group, but no difference in neutrophils. RT-PCR showed decreased expression of macrophage-associated cytokines in the DSF group. Corneal scarring and neovascularization were also suppressed in the DSF group. Low-vacuum scanning electron microscopy imaging showed that macrophage length was significantly shorter in the DSF group, reflecting the reduced extension of pseudopodia. These results suggest that DSF inhibited macrophage infiltration by suppressing macrophage pseudopodia formation.

    DOI: 10.3390/ijms24010735

    PubMed

    researchmap

  • Inhibition of the chemokine signal regulator FROUNT by disulfiram ameliorates crescentic glomerulonephritis. 査読 国際誌

    Etsuko Toda, Anri Sawada, Kazuhiro Takeuchi, Kyoko Wakamatsu, Arimi Ishikawa, Naomi Kuwahara, Yurika Sawa, Saeko Hatanaka, Kana Kokubo, Kosho Makino, Hideyo Takahashi, Yoko Endo, Shinobu Kunugi, Mika Terasaki, Yasuhiro Terasaki, Kouji Matsushima, Yuya Terashima, Akira Shimizu

    Kidney international   102 ( 6 )   1276 - 1290   2022年12月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Activated monocytes/macrophages promote glomerular injury, including crescent formation, in anti-glomerular basement membrane (GBM) glomerulonephritis. Disulfiram, an alcohol-aversion drug, inhibits monocyte/macrophage migration by inhibiting FROUNT, a cytosolic protein that enhances chemokine receptor signaling. Our study found that disulfiram at a human equivalent dose successfully blocked albuminuria and crescent formation with podocyte loss, and later stage kidney fibrotic lesions, in a rat model of anti-GBM glomerulonephritis. A disulfiram derivative, DSF-41, with more potent FROUNT inhibition activity, inhibited glomerulonephritis at a lower dose than disulfiram. Disulfiram markedly reduced the number of monocytes or macrophages at the early stage of glomerulonephritis and that of CD3+ and CD8+ lymphocytes at the established stage. Impaired pseudopodia formation was observed in the glomerular monocytes/macrophages of the disulfiram group; consistent with the in vitro observation that disulfiram blocked chemokine-dependent pseudopodia formation and chemotaxis of bone marrow-derived monocytes/macrophages. Furthermore, disulfiram suppressed macrophage activation as revealed by reduced expression of inflammatory cytokines and chemokines (TNF-α, CCL2, and CXCL9) and reduced CD86 and MHC class II expressions in monocytes/macrophages during glomerulonephritis. The dramatic reduction in monocyte/macrophage number might have resulted from disulfiram suppression of both the chemotactic response of monocytes/macrophages and their subsequent activation to produce cytokines and chemokines, which further recruit monocytes. Additionally, FROUNT was expressed in CD68+ monocytes/macrophages infiltrating the crescentic glomeruli in human anti-GBM glomerulonephritis. Thus, disulfiram can be a highly effective and safe drug for the treatment of glomerulonephritis by blocking the chemotactic responses of monocytes/macrophages and their activation status in the glomerulus.

    DOI: 10.1016/j.kint.2022.07.031

    PubMed

    researchmap

  • The reduced number of nephrons with shortening renal tubules in mouse postnatal adverse environment. 査読 国際誌

    Masako Tagawa, Mika Terasaki, Akiko Mii, Etsuko Toda, Yusuke Kajimoto, Shinobu Kunugi, Yasuhiro Terasaki, Akira Shimizu

    Pediatric research   2022年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The intrauterine adverse environment during nephrogenesis reduces the nephron number, probably associates with impaired ureteric bud (UB) branching. METHODS: The kidneys in C57/BL6 mice were irradiated with a single dose of 10 gray (10 Gy) as adverse environment on postnatal day 3 (irradiated PND3 kidneys) after UB branching ceased. The renal functions and pathological findings of irradiated PND3 kidneys were compared with those of non-irradiated control and 10 Gy irradiation on PND14 (irradiated PND14 kidney) from 1 to 18 months. RESULTS: The number and density of glomeruli in irradiated PND3 kidneys were reduced by 1 month with renal dysfunction at 6 months. The morphologically incomplete glomeruli with insufficient capillaries were involuted by 1 month in the superficial cortex. Reduced tubular numbers and developmental disability with shortening renal tubules occurred in irradiated PND3 kidneys with impaired urine concentration at 6 months. Hypertrophy of glomeruli developed, and occasional sclerotic glomeruli appeared in the juxtamedullary cortex with hypertension and albuminuria at 12 to 18 months. CONCLUSIONS: The reduced number of nephrons with shortening renal tubules occurred with impaired renal functions in a postnatal adverse environment after cessation of UB branching, and glomerular hypertrophy with occasional glomerulosclerosis developed accompanied with hypertension and albuminuria in the adulthood. IMPACT: The reduced number of nephrons with shortening renal tubules occurred with impaired renal functions in a postnatal adverse environment after cessation of ureteric bud branching. The reduced number of glomeruli were associated with not only the impaired formation of glomeruli but also involution of morphologically small incomplete glomeruli after an adverse environment. The insufficiently developed nephrons were characterized by the shortening renal tubules with impaired urine concentration. In addition, glomerular hypertrophy and occasional glomerulosclerosis developed with hypertension and albuminuria in adulthood. The present study can help to understand the risk of alternations of premature nephrons in preterm neonates.

    DOI: 10.1038/s41390-022-02332-0

    PubMed

    researchmap

  • Heavy Metal Enhancement Technique for Diaminobenzidine in Immunohistochemistry Enables Ultrastructural Observation by Low-vacuum Scanning Electron Microscopy. 査読 国際誌

    Yutaka Arai, Kazuhiro Takeuchi, Saeko Hatanaka, Arimi Ishikawa, Taichi Inoue, Shoichiro Takakuma, Yusuke Kajimoto, Etsuko Toda, Shinobu Kunugi, Mika Terasaki, Akira Shimizu

    The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society   70 ( 6 )   427 - 436   2022年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Low-vacuum scanning electron microscopy (LV-SEM) is a powerful tool that allows to observe light microscopic specimens with periodic acid-silver methenamine (PAM) staining at a higher magnification, simply by removing the coverslip. However, it is not suitable for observation of immunohistochemistry (IHC) using 3,3'-diaminobenzidine (DAB) due to insufficient backscattered electron image. Traditional heavy metal enhancement techniques for DAB in IHC, (1) osmium tetroxide and iron, (2) cobalt, (3) methenamine silver (Ag), (4) gold chloride (Gold), and (5) both Ag and Gold (Ag + Gold), were examined by LV-SEM. Tissue specimens from Thy1.1 glomerulonephritis rat kidney stained with α-smooth muscle actin and visualized with DAB were enhanced by each of these enhancement methods. We found, in light microscopic and LV-SEM, that the enhancement with Ag, Gold, or Ag + Gold had better intensity and contrast than others. At a higher magnification, Ag + Gold enhancement showed high intensity and low background, although only Ag or Gold enhancement had nonspecific background. Even after observation by LV-SEM, the quality of specimens was maintained after remounting the coverslip. It was also confirmed that Ag + Gold enhancement could be useful for IHC using clinical human renal biopsy. These findings indicate that Ag + Gold provided an adequate enhancement in IHC for both LM and LV SEM observation.

    DOI: 10.1369/00221554221102996

    PubMed

    researchmap

  • Disulfiram Produces Potent Anxiolytic-Like Effects Without Benzodiazepine Anxiolytics-Related Adverse Effects in Mice. 査読 国際誌

    Akiyoshi Saitoh, Yoshifumi Nagayama, Daisuke Yamada, Kosho Makino, Toshinori Yoshioka, Nanami Yamanaka, Momoka Nakatani, Yoshino Takahashi, Mayuna Yamazaki, Chihiro Shigemoto, Misaki Ohashi, Kotaro Okano, Tomoki Omata, Etsuko Toda, Yoshitake Sano, Hideyo Takahashi, Kouji Matsushima, Yuya Terashima

    Frontiers in pharmacology   13   826783 - 826783   2022年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Disulfiram is an FDA approved drug for the treatment of alcoholism. The drug acts by inhibiting aldehyde dehydrogenase, an enzyme essential to alcohol metabolism. However, a recent study has demonstrated that disulfiram also potently inhibits the cytoplasmic protein FROUNT, a common regulator of chemokine receptor CCR2 and CCR5 signaling. Several studies have reported that chemokine receptors are associated with the regulation of emotional behaviors in rodents, such as anxiety. Therefore, this study was performed to clarify the effect of disulfiram on emotional behavior in rodents. The anxiolytic-like effects of disulfiram were investigated using an elevated plus-maze (EPM) test, a typical screening model for anxiolytics. Disulfiram (40 or 80 mg/kg) significantly increased the amount of time spent in the open arms of the maze and the number of open arm entries without affecting the total open arms entries. Similar results were obtained in mice treated with a selective FROUNT inhibitor, disulfiram-41 (10 mg/kg). These disulfiram-associated behavioral changes were similar to those observed following treatment with the benzodiazepine anxiolytic diazepam (1.5 mg/kg). Moreover, disulfiram (40 mg/kg) significantly and completely attenuated increased extracellular glutamate levels in the prelimbic-prefrontal cortex (PL-PFC) during stress exposure on the elevated open-platform. However, no effect in the EPM test was seen following administration of the selective aldehyde dehydrogenase inhibitor cyanamide (40 mg/kg). In contrast to diazepam, disulfiram caused no sedation effects in the open-field, coordination disorder on a rotarod, or amnesia in a Y-maze. This is the first report suggesting that disulfiram produces anxiolytic-like effects in rodents. We found that the presynaptic inhibitory effects on glutaminergic neurons in the PL-PFC may be involved in its underlying mechanism. Disulfiram could therefore be an effective and novel anxiolytic drug that does not produce benzodiazepine-related adverse effects, such as amnesia, coordination disorder, or sedation, as found with diazepam. We propose that the inhibitory activity of disulfiram against FROUNT function provides an effective therapeutic option in anxiety.

    DOI: 10.3389/fphar.2022.826783

    PubMed

    researchmap

  • Uterine leiomyosarcomas with osteoclast-like giant cells associated with high expression of RUNX2 and RANKL. 査読 国際誌

    Mika Terasaki, Yasuhiro Terasaki, Kyoko Wakamatsu, Naomi Kuwahara, Koichi Yoneyama, Rieko Kawase, Keisuke Kurose, Etsuko Toda, Yoko Endo, Shinobu Kunugi, Yusuke Kajimoto, Akira Shimizu

    Virchows Archiv : an international journal of pathology   478 ( 5 )   893 - 904   2021年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Uterine leiomyosarcoma (ULMS) with osteoclast-like giant cells (OLGCs) has been reported as a rare phenomenon in ULMS, and its clinico-pathological features and tumorigenesis remain unclear. We recently reported high expression of receptor activator of nuclear factor κB ligand (RANKL) in ULMS with OLGCs. As osteoblasts produce RANKL, in this study, we analyzed the expression of Runt-related transcription factor 2 (RUNX2), a critical transcription factor for osteoblasts, and osteoclast-related proteins in three cases of ULMS with OLGCs as well as five conventional ULMSs and nine leiomyomas. Immunohistochemistry and real-time reverse transcription quantitative polymerase chain reaction analyses showed high expression of RUNX2 and RANKL in ULMS with OLGCs. In these cases, macrophages expressed receptor activator of nuclear factor κB (RANK), and OLGCs expressed osteoclast-related proteins (nuclear factor of activated T cells, cytoplasmic 1 (NFATc1), and cathepsin K). Accumulation sites of cathepsin K-positive OLGCs showed hemorrhagic appearance and degraded type IV collagen. We reviewed reported cases of ULMS with OLGCs, including ours, and found that they presented an aggressive course even at stage I. Furthermore, metastatic lesions showed similar histological features to those of OLGC association in ULMS. Here, we show that tumor cells in ULMS with OLGCs highly express RUNX2 and RANKL and that osteoclastic differentiation of macrophages occurs in the tumor tissue.

    DOI: 10.1007/s00428-020-02996-1

    PubMed

    researchmap

  • Rational Design of Monodispersed Mutants of Proteins by Identifying Aggregation Contact Sites Using Solubilizing Agents. 査読 国際誌

    Tatsuichiro Tsuji, Sosuke Yoshinaga, Mitsuhiro Takeda, Takafumi Sato, Akihiro Sonoda, Norihito Ishida, Kaori Yunoki, Etsuko Toda, Yuya Terashima, Kouji Matsushima, Hiroaki Terasawa

    Biochemistry   59 ( 39 )   3639 - 3649   2020年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Suppression of protein aggregation is a subject of growing importance in the treatment of protein aggregation diseases, an urgent worldwide human health problem, and the production of therapeutic proteins, such as antibody drugs. We previously reported a method to identify compounds that suppress aggregation, based on screening using multiple terminal deletion mutants. We now present a method to determine the aggregation contact sites of proteins, using such solubilizing compounds, to design monodispersed mutants. We applied this strategy to the chemokine receptor-binding domain (CRBD) of FROUNT, which binds to the membrane-proximal C-terminal intracellular region of CCR2. Initially, the backbone NMR signals were assigned to a certain extent by available methods, and the putative locations of five α-helices were identified. Based on NMR chemical shift perturbations upon varying the protein concentrations, the first and third helices were found to contain the aggregation contact sites. The two helices are amphiphilic, and based on an NMR titration with 1,6-hexanediol, a CRBD solubilizing compound, the contact sites were identified as the hydrophobic patches located on the hydrophilic sides of the two helices. Subsequently, we designed multiple mutants targeting amino acid residues on the contact sites. Based on their NMR spectra, a doubly mutated CRBD (L538E/P612S) was selected from the designed mutants, and its monodispersed nature was confirmed by other biophysical methods. We then assessed the CCR2-binding activities of the mutants. Our method is useful for the protein structural analyses, the treatment of protein aggregation diseases, and the improvement of therapeutic proteins.

    DOI: 10.1021/acs.biochem.0c00414

    PubMed

    researchmap

  • 1H, 13C and 15N resonance assignments for a chemokine receptor-binding domain of FROUNT, a cytoplasmic regulator of chemotaxis. 査読 国際誌

    Sosuke Yoshinaga, Norihito Ishida, Tatsuichiro Tsuji, Akihiro Sonoda, Kaori Yunoki, Mitsuhiro Takeda, Etsuko Toda, Yuya Terashima, Kouji Matsushima, Hiroaki Terasawa

    Biomolecular NMR assignments   12 ( 2 )   259 - 262   2018年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    FROUNT is a cytoplasmic protein that interacts with the membrane-proximal C-terminal regions (Pro-Cs) of the CCR2 and CCR5 chemokine receptors. The interactions between FROUNT and the chemokine receptors play an important role in the migration of inflammatory immune cells. Therefore, FROUNT is a potential drug target for inflammatory diseases. However, the structural basis of the interactions between FROUNT and the chemokine receptors remains to be elucidated. We previously identified the C-terminal region (residues 532-656) of FROUNT as the structural domain responsible for the Pro-C binding, referred to as the chemokine receptor-binding domain (CRBD), and then constructed its mutant, bearing L538E/P612S mutations, with improved NMR spectral quality, referred to as CRBD_LEPS. We now report the main-chain and side-chain 1H, 13C, and 15N resonance assignments of CRBD_LEPS. The NMR signals of CRBD_LEPS were well dispersed and their intensities were uniform on the 1H-15N HSQC spectrum, and thus almost all of the main-chain and side-chain resonances were assigned. This assignment information provides the foundation for NMR studies of the three-dimensional structure of CRBD_LEPS in solution and its interactions with chemokine receptors.

    DOI: 10.1007/s12104-018-9819-2

    PubMed

    researchmap

  • Efficient identification of compounds suppressing protein precipitation via solvent screening using serial deletion mutants of the target protein. 査読 国際誌

    Kaori Yunoki, Sosuke Yoshinaga, Mitsuhiro Takeda, Ryohei Nagano, Yusuke Tsuchiya, Akihiro Sonoda, Tatsuichiro Tsuji, Makoto Hirakane, Etsuko Toda, Yuya Terashima, Kouji Matsushima, Hiroaki Terasawa

    Genes to cells : devoted to molecular & cellular mechanisms   23 ( 2 )   70 - 79   2018年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Blackwell Publishing Ltd  

    The control of protein solubility is a subject of broad interest. Although several solvent screening methods are available to search for compounds that enhance protein solubilization, their performance is influenced by the intrinsic solubility of the tested protein. We now present a method for screening solubilizing compounds, using an array of N- or C-terminal deletion mutants of the protein. A key behind this approach is that such terminal deletions of the protein affect its aggregation propensity. The solubilization activities of trial solvents are individually assessed, based on the number of solubilized mutants. The solubilizing compounds are then identified from the screened solvents. In this study, the C-terminal chemokine receptor-binding region of the cytoplasmic protein, FROUNT (FNT-C), which mediates intracellular signals leading to leukocyte migration, was subjected to the multicomponent screening. In total, 192 solution conditions were tested, using eight terminal deletion mutants of FNT-C. We identified five solvent conditions that solubilized four or five mutants of FNT-C, and the compounds in the screened solvents were then, respectively, assessed in terms of their solubilization ability. The best compound for solubilizing FNT-C was 1,6-hexanediol. Indeed, 1,6-hexanediol bound to FNT-C and suppressed its precipitation, as showed by NMR and dynamic light scattering analyses.

    DOI: 10.1111/gtc.12554

    Scopus

    PubMed

    researchmap

  • Identification and Preparation of a Novel Chemokine Receptor-Binding Domain in the Cytoplasmic Regulator FROUNT. 査読 国際誌

    Akihiro Sonoda, Sosuke Yoshinaga, Kaori Yunoki, Soichiro Ezaki, Kotaro Yano, Mitsuhiro Takeda, Etsuko Toda, Yuya Terashima, Kouji Matsushima, Hiroaki Terasawa

    Molecular biotechnology   59 ( 4-5 )   141 - 150   2017年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:HUMANA PRESS INC  

    FROUNT is a cytoplasmic protein that binds to the membrane-proximal C-terminal regions (Pro-Cs) of chemokine receptors, CCR2 and CCR5. The FROUNT-chemokine receptor interactions play a pivotal role in the migration of inflammatory immune cells, indicating the potential of FROUNT as a drug target for inflammatory diseases. To provide the foundation for drug development, structural information of the Pro-C binding region of FROUNT is desired. Here, we defined the novel structural domain (FNT-CB), which mediates the interaction with the chemokine receptors. A recombinant GST-tag-fused FNT-CB protein expression system was constructed. The protein was purified by affinity chromatography and then subjected to in-gel protease digestion of the GST-tag. The released FNT-CB was further purified by anion-exchange and size-exclusion chromatography. Purified FNT-CB adopts a helical structure, as indicated by CD. NMR line-broadening indicated that weak aggregation occurred at sub-millimolar concentrations, but the line-broadening was mitigated by using a deuterated sample in concert with transverse relaxation-optimized spectroscopy. The specific binding of FNT-CB to CCR2 Pro-C was confirmed by the fluorescence-based assay. The improved NMR spectral quality and the retained functional activity of FNT-CB support the feasibility of further structural and functional studies targeted at the anti-inflammatory drug development.

    DOI: 10.1007/s12033-017-0002-2

    Web of Science

    PubMed

    researchmap

  • Robust Antitumor Effects of Combined Anti-CD4-Depleting Antibody and Anti-PD-1/PD-L1 Immune Checkpoint Antibody Treatment in Mice. 査読 国際誌

    Satoshi Ueha, Shoji Yokochi, Yoshiro Ishiwata, Haru Ogiwara, Krishant Chand, Takuya Nakajima, Kosuke Hachiga, Shigeyuki Shichino, Yuya Terashima, Etsuko Toda, Francis H W Shand, Kazuhiro Kakimi, Satoru Ito, Kouji Matsushima

    Cancer immunology research   3 ( 6 )   631 - 40   2015年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:AMER ASSOC CANCER RESEARCH  

    Depletion of CD4(+) cells in tumor-bearing mice has strong antitumor effects. However, the mechanisms underlying these effects and the therapeutic benefits of CD4(+) cell depletion relative to other immunotherapies have not been fully evaluated. Here, we investigated the antitumor effects of an anti-CD4-depleting mAb as a monotherapy or in combination with immune checkpoint mAbs. In B16F10, Colon 26, or Lewis lung carcinoma subcutaneous tumor models, administration of the anti-CD4 mAb alone had strong antitumor effects that were superior to those elicited by CD25(+) Treg depletion or other immune checkpoint mAbs, and which were completely reversed by CD8(+) cell depletion. CD4(+) cell depletion led to the proliferation of tumor-specific CD8(+) T cells in the draining lymph node and increased infiltration of PD-1(+)CD8(-) T cells into the tumor, with a shift toward type I immunity within the tumor. Combination treatment with the anti-CD4 mAb and immune checkpoint mAbs, particularly anti-PD-1 or anti-PD-L1 mAbs, synergistically suppressed tumor growth and greatly prolonged survival. To our knowledge, this work represents the first report of robust synergy between anti-CD4 and anti-PD-1 or anti-PD-L1 mAb therapies. (C)2015 AACR.

    DOI: 10.1158/2326-6066.CIR-14-0190

    Web of Science

    PubMed

    researchmap

  • Structural basis for the binding of the membrane-proximal C-terminal region of chemokine receptor CCR2 with the cytosolic regulator FROUNT. 査読 国際誌

    Kaori Esaki, Sosuke Yoshinaga, Tatsuichiro Tsuji, Etsuko Toda, Yuya Terashima, Takashi Saitoh, Daisuke Kohda, Toshiyuki Kohno, Masanori Osawa, Takumi Ueda, Ichio Shimada, Kouji Matsushima, Hiroaki Terasawa

    The FEBS journal   281 ( 24 )   5552 - 66   2014年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Blackwell Publishing Ltd  

    The membrane-proximal C-terminal region (Pro-C) is important for the regulation of G-protein-coupled receptors (GPCRs), but the binding of the Pro-C region to a cytosolic regulator has not been structurally analyzed. The chemokine receptor CCR2 is a member of the GPCR superfamily, and the Pro-C region of CCR2 binds to the cytosolic regulator FROUNT. Studying the interaction between CCR2 Pro-C and FROUNT at an atomic level provides a basis for understanding the signal transduction mechanism via GPCRs. NOE-based NMR experiments showed that, when bound to FROUNT, CCR2 Pro-C adopted a helical conformation, as well as when embedded in dodecylphosphocholine micelles. A comparison of two types of cross-saturation-based NMR experiments, applied to a three-component mixture of Pro-C, FROUNT and micelles or a two-component mixture of Pro-C and micelles, revealed that the hydrophobic binding surface on Pro-C for FROUNT mostly overlapped with the binding site for micelles, suggesting competitive binding of Pro-C between FROUNT and micelles. Leu316 was important for both FROUNT and micelle binding. Phe319 was newly identified to be crucial for FROUNT binding, by NMR and mutational analyses. The association and dissociation rates of CCR2 Pro-C for lipid bilayer biomembranes were faster than those for FROUNT. We previously reported that FROUNT binding to CCR2 is detectable even in unstimulated cells and increases in response to chemokine stimulation. Taken together, these results support a model of CCR2 equilibrium: chemokine binding changes the conformational equilibrium of CCR2 toward the active state, and Pro-C switches its binding partner from the membrane to FROUNT.

    DOI: 10.1111/febs.13096

    Web of Science

    Scopus

    PubMed

    researchmap

  • Identification of a binding element for the cytoplasmic regulator FROUNT in the membrane-proximal C-terminal region of chemokine receptors CCR2 and CCR5. 査読 国際誌

    Etsuko Toda, Yuya Terashima, Kaori Esaki, Sosuke Yoshinaga, Minoru Sugihara, Yutaka Kofuku, Ichio Shimada, Makiko Suwa, Shiro Kanegasaki, Hiroaki Terasawa, Kouji Matsushima

    The Biochemical journal   457 ( 2 )   313 - 22   2014年1月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:PORTLAND PRESS LTD  

    Chemokine receptors mediate the migration of leucocytes during inflammation. The cytoplasmic protein FROUNT binds to chemokine receptors CCR2 [chemokine (C-C motif) receptor 2] and CCR5, and amplifies chemotactic signals in leucocytes. Although the interaction between FROUNT and chemokine receptors is important for accurate chemotaxis, the interaction mechanism has not been elucidated. In the present study we identified a 16-amino-acid sequence responsible for high-affinity binding of FROUNT at the membrane-proximal C-terminal intracellular region of CCR2 (CCR2 Pro-C) by yeast two-hybrid analysis. Synthesized peptides corresponding to the CCR2 Pro-C sequence directly interacted with FROUNT in vitro. CCR2 Pro-C was predicted to form an amphipathic helix structure. Residues on the hydrophobic side are completely conserved among FROUNT-binding receptors, suggesting that the hydrophobic side is the responsible element for FROUNT binding. The L316T mutation to the hydrophobic side of the predicted helix decreased the affinity for FROUNT. Co-immunoprecipitation assays revealed that the CCR2 L316T mutation diminished the interaction between FROUNT and full-length CCR2 in cells. Furthermore, this mutation impaired the ability of the receptor to mediate chemotaxis. These findings provide the first description of the functional binding element in helix 8 of CCR2 for the cytosolic regulator FROUNT that mediates chemotactic signalling.

    DOI: 10.1042/BJ20130827

    Web of Science

    PubMed

    researchmap

  • Am80, a Retinoic Acid Receptor Agonist, Ameliorates Murine Vasculitis Through the Suppression of Neutrophil Migration and Activation 査読

    Chie Miyabe, Yoshishige Miyabe, Noriko N. Miura, Kei Takahashi, Yuya Terashima, Etsuko Toda, Fumiko Honda, Tomohiro Morio, Naoko Yamagata, Naohito Ohno, Koichi Shudo, Jun-ichi Suzuki, Mitsuaki Isobe, Kouji Matsushima, Ryoji Tsuboi, Nobuyuki Miyasaka, Toshihiro Nanki

    ARTHRITIS AND RHEUMATISM   65 ( 2 )   503 - 512   2013年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY-BLACKWELL  

    Objective. Vasculitis is characterized by leukocyte infiltration in the vessel walls, with destructive damage to mural structures. Retinoids are compounds that bind to retinoic acid receptors and exert biologic activities similar to those of vitamin A, including modulatory effects on cell proliferation and differentiation. This study was undertaken to examine the therapeutic effects of a synthetic retinoid, Am80, in a murine model of vasculitis induced by Candida albicans water-soluble fraction (CAWS).
    Methods. Vasculitis was induced in BALB/c mice by intraperitoneal injection of CAWS. Neutrophils were depleted by injection of antineutrophil antibody-positive serum. Am80 was administered orally once daily. Vasculitis was evaluated histologically. Migration of labeled adoptively transferred cells was quantified. Chemotaxis was assessed by cell mobility analysis. Production of reactive oxygen species (ROS) and phosphorylation of MAPKs were measured by flow cytometry. Concentrations of elastase were measured by enzyme-linked immunosorbent assay.
    Results. Administration of CAWS induced vasculitis in the coronary arteries and aortic root, with abundant neutrophil infiltration. Depletion of neutrophils reduced CAWS-induced vasculitis. Treatment with Am80 led to a significant attenuation of the vasculitis score and inhibition of the migration of transferred neutrophils into the site of vasculitis. In vitro, Am80 suppressed fMLP-induced chemotaxis of human peripheral blood neutrophils. ROS production and elastase release by stimulated neutrophils were reduced by AM80 treatment, and Am80 also inhibited phosphorylation of ERK-1/2 and p38 in neutrophils stimulated with fMLP plus lipopolysaccharide.
    Conclusion. Am80 significantly suppressed CAWS-induced vasculitis. This effect was presumably exerted via inhibition of neutrophil migration and activation.

    DOI: 10.1002/art.37784

    Web of Science

    researchmap

  • Expression and purification of human FROUNT, a common cytosolic regulator of CCR2 and CCR5. 査読 国際誌

    Kaori Esaki, Yuya Terashima, Etsuko Toda, Sosuke Yoshinaga, Norie Araki, Kouji Matsushima, Hiroaki Terasawa

    Protein expression and purification   77 ( 1 )   86 - 91   2011年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ACADEMIC PRESS INC ELSEVIER SCIENCE  

    Chemokine receptors play pivotal roles for immune cell recruitment to inflammation sites, in response to chemokine gradients (chemotaxis). The mechanisms of chemokine signaling, especially the initiation of the intracellular signaling cascade, are not well understood. We previously identified a cytoplasmic protein FROUNT, which binds to the C-terminal regions of CCR2 and CCR5 to mediate chemokine signaling. Although large amounts of purified protein are required for detailed biochemical studies and drug screening, no method to produce recombinant FROUNT has been reported. In this study, we developed a method for the production of recombinant human FROUNT. Human FROUNT was successfully expressed in Escherichia coli, as a soluble protein fused to the folding chaperone Trigger Factor, with a cold shock expression system. The purified FROUNT protein displayed CCR2 binding ability without any additional components, as demonstrated by SPR measurements. A gel filtration analysis suggested that FROUNT exists in a homo-oligomeric state. This high-yield method is cost-effective for human FROUNT production. It should be a powerful tool for further biochemical and structural studies to elucidate GPCR regulation and chemokine signaling, and also will contribute to drug development. (c) 2010 Elsevier Inc. All rights reserved.

    DOI: 10.1016/j.pep.2010.12.012

    Web of Science

    PubMed

    researchmap

  • Chemokines in inflammatory and immune diseases

    Matsushima Kouji, Terashima Yuya, Toda Etsuko, Shand Francis, Ueha Satoshi

    Inflammation and Regeneration   31 ( 1 )   11 - 22   2011年

     詳細を見る

    記述言語:英語   出版者・発行元:The Japanese Society of Inflammation and Regeneration  

    Nearly two decades have passed since our discovery of the prototypic chemokines, a neutrophil chemotactic factor interleukin 8 (IL 8, CXCL8) and monocyte chemotactic factor MCAF/MCP-1 (CCL2) at the National Cancer Institute, USA. The characterization of chemokines has revealed the molecular mechanisms underlying specific leukocyte subset infiltration into inflammatory tissues, previously a long-standing enigma in inflammation research. In this review we briefly recount the chronology of chemokine research, then overview chemokine receptor signal transduction systems, chemokines in inflammation and immunity, chemokines in HIV infection and cancer, and the current status of therapeutic approaches targeting chemokines and their receptors.

    DOI: 10.2492/inflammregen.31.11

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2012103174

  • FROUNT is a common regulator of CCR2 and CCR5 signaling to control directional migration. 査読 国際誌

    Etsuko Toda, Yuya Terashima, Tsuyoshi Sato, Kenzo Hirose, Shiro Kanegasaki, Kouji Matsushima

    Journal of immunology (Baltimore, Md. : 1950)   183 ( 10 )   6387 - 94   2009年11月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:AMER ASSOC IMMUNOLOGISTS  

    FROUNT is a known CCR2-binding protein that facilitates monocyte/macrophage infiltration. Here we report that FROUNT also hinds to the C-terminal region of CCR5 and enhances CCR5-mediated cellular chemotaxis. We show that FROUNT overexpression enhances the directionality of chemotaxis, while FROUNT suppression results in impaired responsiveness. Furthermore, we found an increase in consolidated pseudopodium formation in FROUNT-overexpressing cells (FNT cells) on uniform stimulation with CCL4 (MIP1-beta), a specific ligand of CCR5. In most FNT cells, one to two pseudopodia directed toward higher chemokine concentration were found, whereas most FNT-suppressed cells had multiple pseudopodia. The data indicate that FROUNT is involved in sensing and amplifying a shallow extracellular chemokine gradient that leads to a limited number of accurate pseudopodia directed toward the chemokine concentration. In addition to its separate roles in CCR2- and CCR5-mediated chemotaxis, FROUNT, as a common regulator of these receptors, possibly plays a crucial role in the recruitment of immune cells expressing these receptors. The Journal of Immunology, 2009, 183: 6387-6394.

    DOI: 10.4049/jimmunol.0803469

    Web of Science

    PubMed

    researchmap

  • Plasmacytoid DCs help lymph node DCs to induce anti-HSV CTLs 査読

    H Yoneyama, K Matsuno, E Toda, T Nishiwaki, N Matsuo, A Nakano, S Narumi, B Lu, C Gerard, S Ishikawa, K Matsushima

    JOURNAL OF EXPERIMENTAL MEDICINE   202 ( 3 )   425 - 435   2005年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ROCKEFELLER UNIV PRESS  

    Antiviral cell-mediated immunity is initiated by the dendritic cell ( DC) network in lymph nodes (LNs). Plasmacytoid DCs (pDCs) are known to migrate to inflamed LNs and produce interferon (IFN)-alpha, but their other roles in antiviral T cell immunity are unclear. We report that LN-recruited pDCs are activated to create local immune fields that generate antiviral cytotoxic T lymphocytes ( CTLs) in association with LNDCs, in a model of cutaneous herpes simplex virus (HSV) infection. Although pDCs alone failed to induce CTLs, in vivo depletion of pDCs impaired CTL-mediated virus eradication. LNDCs from pDC-depleted mice showed impaired cluster formation with T cells and antigen presentation to prime CTLs. Transferring circulating pDC precursors from wild-type, but not CXCR3-deficient, mice to pDC-depleted mice restored CTL induction by impaired LNDCs. In vitro co-culture experiments revealed that pDCs provided help signals that recovered impaired LNDCs in a CD2- and CD40L-dependent manner. pDC-derived IFN-alpha further stimulated the recovered LNDCs to induce CTLs. Therefore, the help provided by pDCs for LNDCs in primary immune responses seems to be pivotal to optimally inducing anti-HSV CTLs.

    DOI: 10.1084/jem.20041961

    Web of Science

    PubMed

    researchmap

  • Splenic Dendritic Cells from Antigen-Fed Mice Induced Antigen-Specific T Cell Unresponsiveness in vivo. 査読 国際誌

    Masanobu Hibi, Satoshi Hachimura, Toshiko Somaya, Etsuko Toda, Masaaki Hashiguchi, Tsuyoshi Takayama, Kastumi Sasaki, Takashi Senga, Shuichi Hashizume, Shuichi Kaminogawa

    Cytotechnology   43 ( 1-3 )   41 - 8   2003年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:KLUWER ACADEMIC PUBL  

    While it is well-known that orally fed antigens induce systemic T cell tolerance ( oral tolerance), the mechanism by which this occurs, however, remains unclear. In the present study, we examined the role of splenic dendritic cells (DCs) in the process of oral tolerance induction and/or maintenance, by using an adoptive transfer system of antigen (Ag)-specific CD4(+) T cells from ovalbumin (OVA)-specific T cell receptor transgenic mice and DCs from OVA-fed BALB/c mice. Transfer of splenic DCs from OVA-fed mice reduced IL-2 productivity and the proliferative activity of pre-transferred Ag-specific CD4(+) T cells to ex vivo Ag stimulation. There were no changes in expression levels of costimulatory molecules on DCs from OVA-fed mice. Our results show that orally administered Ags induce systemic T cell unresponsiveness through splenic DCs without inducing cell division of T cells, thus providing evidence that splenic DCs are involved in oral tolerance induction.

    DOI: 10.1023/B:

    Web of Science

    PubMed

    researchmap

  • CD11b(+) Peyer's patch dendritic cells secrete IL-6 and induce IgA secretion from naive B cells 査読

    A Sato, M Hashiguchi, E Toda, A Iwasaki, S Hachimura, S Kaminogawa

    JOURNAL OF IMMUNOLOGY   171 ( 7 )   3684 - 3690   2003年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:AMER ASSOC IMMUNOLOGISTS  

    Peyer's patch (PP) dendritic cells (DCs) have been shown to exhibit a distinct capacity to induce cytokine secretion from CD4(+) T cells compared with DCs in other lymphoid organs such as the spleen (SP). In this study, we investigated whether PP DCs are functionally different from DCs in the SP in their ability to induce Ab production from B cells. Compared with SP DCs, freshly isolated PP DCs induced higher levels of IgA secretion from naive B cells in DC-T cell-B cell coculture system in vitro. The IgA production induced by PP DCs was attenuated by neutralization of IL-6. In addition, the induction of IgA secretion by SP DCs, but not PP DCs, was further enhanced by the addition of exogenous IL-6. Finally, we demonstrated that only PP CD11b(+) DC subset secreted higher levels of IL-6 compared with other DC subsets in the PP and all SP DC populations, and that PP CD11b(+) DC induced naive B cells to produce higher levels of IgA compared with SP CD11b(+) DC. These results suggest a unique role of PP CD11b(+) DCs in enhancing IgA production from B cells via secretion of IL-6.

    DOI: 10.4049/jimmunol.171.7.3684

    Web of Science

    PubMed

    researchmap

▼全件表示

MISC

  • IgA腎症における糸球体周囲新生微小血管

    清水 章, 鎌野 千佐子, 三井 亜希子, 高熊 将一朗, 梶本 雄介, 遠田 悦子, 功刀 しのぶ, 寺崎 美佳, 寺崎 泰弘

    日本病理学会会誌   112 ( 1 )   279 - 279   2023年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本病理学会  

    researchmap

  • ラット角膜アルカリ外傷モデルにおける前眼部炎症によるZinn小帯変化の観察

    高橋 慶, 有馬 武志, 中野 優治, 飛田 悠太朗, 遠田 悦子, 清水 章, 高橋 浩

    日本眼科学会雑誌   127 ( 臨増 )   237 - 237   2023年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(公財)日本眼科学会  

    researchmap

  • Disulfiram点眼薬の角膜炎症抑制効果の検討

    池袋 東陽, 笠松 桃子, 高橋 慶, 後藤 均, 中野 優治, 飛田 悠太朗, 有馬 武志, 内山 昌明, 遠田 悦子, 寺島 裕也, 清水 章, 高橋 浩

    日本眼科学会雑誌   126 ( 臨増 )   255 - 255   2022年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(公財)日本眼科学会  

    researchmap

  • 最先端医療の今 マクロファージの動きを制御するFROUNTによるがん免疫応答の修飾作用

    遠田 悦子, 寺島 裕也

    Medical Science Digest   47 ( 3 )   170 - 171   2021年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)ニュー・サイエンス社  

    がんの治療薬は格段に進歩し、免疫チェックポイント阻害薬の登場によって、がん細胞そのものを叩く手法に加えて、もともと備わっているがん細胞に対する免疫応答を強めるがん免疫療法に治療の軸が置かれようとしている。そこに立ちはだかるのが、本来は異物を排除し、生体防御に働くはずのマクロファージである。がん組織に存在するマクロファージは、がん細胞の増殖や転移を促進し、がん免疫応答を抑制する性質に変化している。我々は、マクロファージの"動き"を制御する分子FROUNTに着目し、FROUNTのがんにおける働きの解析と、制御薬の開発を行ってきた。FROUNTはマクロファージががん組織に浸潤するステップと、がん組織でがん細胞と共存した際の活性化を促進し、マクロファージによるがん細胞の増殖促進作用に関与することが明らかになった。FROUNTを標的とすることにより、世界で初めてマクロファージを制御する治療薬の実現を目指す。(著者抄録)

    J-GLOBAL

    researchmap

  • 破骨細胞様巨細胞を伴う子宮平滑筋肉腫におけるRUNX2、RANKL高発現と破骨細胞分化

    寺崎 美佳, 寺崎 泰弘, 桑原 尚美, 若松 恭子, 柳 雅人, 遠田 悦子, 梶本 雄介, 遠藤 陽子, 功刀 しのぶ, 清水 章

    日本病理学会会誌   110 ( 1 )   339 - 339   2021年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本病理学会  

    researchmap

  • FROUNTは免疫チェックポイント阻害薬の障壁となるがん促進マクロファージを制御する-古い薬が新たながん免疫療法の扉を拓いた

    寺島裕也, 遠田悦子

    医学のあゆみ   276 ( 2 )   158 - 159   2021年1月

     詳細を見る

  • アルコール依存症治療薬ジスルフィラムによるがん抑制効果の分子標的

    遠田悦子, 寺島裕也

    月刊糖尿病・内分泌代謝科   52 ( 1 )   37 - 44   2021年1月

     詳細を見る

  • ケモカイン受容体会合分子FROUNTのがん進展への関与

    遠田 悦子, 寺島 裕也, 清水 章, 松島 綱治

    日本薬学会年会要旨集   140年会   26Z - am10   2020年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(公社)日本薬学会  

    researchmap

  • 腫瘍免疫応答の正負の調節機構 10.がん免疫応答にかかわるサイトカイン・ケモカインの応用研究

    遠田悦子, 遠田悦子, 寺島裕也, 松島綱治

    実験医学   37 ( 15 )   86 - 91   2019年9月

     詳細を見る

  • 破骨細胞様巨細胞を伴う腫瘍の組織学的類似性およびRANKL発現の検討 査読

    寺崎 美佳, 若松 恭子, 桑原 尚美, 寺崎 泰弘, 遠藤 陽子, 遠田 悦子, 功刀 しのぶ, 梶本 雄介, 清水 華, 清水 章

    日本病理学会会誌   108 ( 2 )   116 - 116   2019年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本病理学会  

    researchmap

  • 破骨細胞様巨細胞を伴う腫瘍の組織学的類似性およびRANKL発現の検討

    寺崎 美佳, 若松 恭子, 桑原 尚美, 寺崎 泰弘, 遠藤 陽子, 遠田 悦子, 功刀 しのぶ, 梶本 雄介, 清水 華, 清水 章

    日本病理学会会誌   108 ( 2 )   116 - 116   2019年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本病理学会  

    researchmap

  • ケモカイン受容体会合分子フロントを標的とした腫瘍促進性マクロファージ制御抗がん薬の開発

    寺島裕也, 遠田悦子, 奥村和弘, 板倉明司, 永瀬浩喜, 松島綱治

    日本インターフェロン・サイトカイン学会学術集会抄録集   83rd   91   2018年7月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • BOLD-fMRI evaluation of different types of analgesic agents on allodynia-specific pain in a rat chronic pain model. 査読

    Sameshima, M, Yuzuriha, N, Yoshinaga, S, Ezaki, S, Ishida, N, Takeda, M, Terashima, Y, Toda, E, Matsushima, K, Terasawa, H

    Proc. Intl. Soc. Mag. Reson. Med.   in press   2018年

     詳細を見る

    記述言語:英語  

    researchmap

  • Structural characterization of the chemokine receptor binding protein, R1-15

    Hiroko Takasaki, Sosuke Yoshinaga, Soichiro Ezaki, Mitsuhiro Takeda, Yuya Terashima, Etsuko Toda, Kouji Matsushima, Hiroaki Terasawa

    CYTOKINE   100   127 - 127   2017年12月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD  

    Web of Science

    researchmap

  • FROUNT is a novel target to control chemotactic response of tumor-associated macrophage

    Yuya Terashima, Etsuko Toda, Meiji Itakura, Kazuhiro Okumura, Hiroki Nagase, Kouji Matsushima

    CYTOKINE   100   186 - 187   2017年12月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD  

    Web of Science

    researchmap

  • A pivotal region for FROUNT-mediated chemotactic signaling that is shared by inflammatory chemokine receptors CCR2 and CCR5

    Etsuko Toda, Yuya Terashima, Sosuke Yoshinaga, Hiroaki Terasawa, Kouji Matsushima

    CYTOKINE   100   186 - 186   2017年12月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD  

    Web of Science

    researchmap

  • マクロファージ制御による新たながん治療薬の開発 (特集 複合がん免疫療法の時代来る)

    寺島 裕也, 遠田 悦子

    細胞   48 ( 13 )   624 - 628   2016年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:ニューサイエンス社  

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2017082748

  • ケモカイン受容体―細胞内制御因子フロント間相互作用の構造生物学的解析

    吉永壮佐, 江崎芳, 辻辰一朗, 遠田悦子, 寺島裕也, 齊藤貴士, 神田大輔, 河野俊之, 大澤匡範, 上田卓見, 嶋田一夫, 松島綱治, 寺沢宏明

    Abstr Annu Meet NMR Soc Jpn   53rd   132 - 133   2014年11月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 細胞遊走制御因子FROUNTとケモカイン受容体との複合体の構造生物学的研究

    辻辰一朗, 吉永壮佐, 日隈, 江崎芳, 寺島裕也, 遠田悦子, 河野俊之, 齊藤貴士, 神田大輔, 嶋田一夫, 松島綱治, 寺沢宏明

    日本薬学会年会要旨集(CD-ROM)   134th   2014年

     詳細を見る

  • ケモカイン受容体CCR2,CCR5とシグナル促進分子フロント

    遠田 悦子, 寺島 裕也

    臨床免疫・アレルギー科   59 ( 3 )   386 - 391   2013年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:科学評論社  

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2013182755

  • 2P028 ケモカインシグナル細胞内制御因子FROUNTとその受容体認識に関する構造生物学的研究(01B.蛋白質:構造機能相関,ポスター,日本生物物理学会年会第51回(2013年度))

    Yoshinaga Sosuke, Tsuji Tatsuichiro, Sonoda Akihiro, Ishida Norihito, Tsuchiya Yusuke, Esaki Kaori, Terashima Yuya, Toda Etsuko, Saitoh Takashi, Kohda Daisuke, Shimada Ichio, Matsushima Kouji, Terasawa Hiroaki

    生物物理   53 ( 1 )   S163   2013年

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本生物物理学会  

    DOI: 10.2142/biophys.53.S163_4

    researchmap

  • 慢性炎症の鍵分子であるケモカイン受容体CCR2/5―フロント間相互作用に関する構造解析と創薬開発 (特集 蛋白構造 : 機能連関解析と治療薬開発への応用)

    江崎 芳, 吉永 壮佐, 遠田 悦子

    内分泌・糖尿病・代謝内科   35 ( 6 )   500 - 507   2012年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:科学評論社  

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2013090584

  • [Molecular targeting drugs for immune and inflammatory diseases]. 査読

    Etsuko Toda, Yuya Terashima, Kouji Matsushima

    Nihon rinsho. Japanese journal of clinical medicine   70 Suppl 8   365 - 71   2012年11月

     詳細を見る

    記述言語:日本語  

    PubMed

    researchmap

  • Am80, a Retinoic Acid Receptor Agonist, Ameliorates Murine Vasculit-isthrough the Suppression of Neutrophil Migration and Activation

    Chie Miyabe, Yoshishige Miyabe, Noriko Miura, Kei Takahashi, Yuya Terashima, Etsuko Toda, Fumiko Honda, Tomohiro Morio, Naohito Ohno, Jun-ichi Suzuki, Mitsuaki Isobe, Kouji Matsushima, Ryoji Tsuboi, Nobuyuki Miyasaka, Toshihiro Nanki

    ARTHRITIS AND RHEUMATISM   64 ( 10 )   S373 - S374   2012年10月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:WILEY-BLACKWELL  

    Web of Science

    researchmap

  • ケモカイン受容体と制御因子FROUNTとの相互作用に関する構造生物学的研究

    江崎芳, 薗田晃弘, 吉永壮佐, 河野俊之, 嶋田一夫, 寺島裕也, 寺島裕也, 遠田悦子, 松島綱治, 寺沢宏明

    日本蛋白質科学会年会プログラム・要旨集   10th   2010年

     詳細を見る

  • ケモカイン受容体の細胞内シグナル伝達機構に関する構造生物学的研究

    江崎芳, 本多美由紀, 吉永壮佐, 荒木令江, 河野俊之, 寺島裕也, 寺島裕也, 遠田悦子, 松島綱治, 寺沢宏明

    日本蛋白質科学会年会プログラム・要旨集   9th   2009年

     詳細を見る

  • [FROUNT, a regulator of monocytes/macrophage chemotaxis]. 査読

    Etsuko Toda, Yuya Terashima

    Seikagaku. The Journal of Japanese Biochemical Society   79 ( 10 )   972 - 5   2007年10月

     詳細を見る

    記述言語:日本語   掲載種別:書評論文,書評,文献紹介等   出版者・発行元:JAPANESE BIOCHEMICAL SOC  

    Web of Science

    PubMed

    researchmap

▼全件表示

講演・口頭発表等

  • FROUNT inhibitor disulfiram ameliorates crescentic glomerulonephritis through the inhibition of monocytes/macrophage migration and activation

    Etsuko Toda, Anri Sawada, Kazuhiro Takeuchi, Shinobu Kunugi, Mika Terasaki, Yasuhiro Terasaki, Kouji Matsushima, Yuya Terashima, Akira Shimizu

    第51回日本免疫学会学術集会  2022年12月 

     詳細を見る

    開催年月日: 2022年12月

    記述言語:英語   会議種別:口頭発表(一般)  

    researchmap

  • A chemokine signal amplifier FROUNT regulates tumor cell-mediated macrophage activation and migration to tumor sites

    Etsuko Toda, Yuya Terashima, Koji Matsushima

    第48回日本免疫学会学術集会  2019年12月 

     詳細を見る

  • A cell migration-promoting molecule FROUNT regulates macrophage activation

    Etsuko Toda, Yuya Terashima, Koji Matsushima

    第50回日本免疫学会学術集会  2021年12月 

     詳細を見る

  • ケモカイン受容体CCR2/CCR5シグナル制御因子FROUNTは マクロファージの炎症性サイトカイン発現を調節する

    遠田悦子, 竹内和博, 寺崎美佳, 功刀しのぶ, 寺崎泰弘, 寺島裕也, 清水章

    第113回日本病理学会総会  2024年3月 

     詳細を見る

    会議種別:口頭発表(一般)  

    researchmap

  • CCR2/5-associated FROUNT regulates macrophage cytokine expression through modulation of MAP kinase pathway

    Etsuko Toda, Kouji Matsushima, Yuya Terashima, Akira Shimizu

    第52回日本免疫学会学術集会  2024年1月 

     詳細を見る

    会議種別:ポスター発表  

    researchmap

  • FROUNT阻害剤ジスルフィラムによる半月体形成性糸球体腎炎抑制効果

    遠田悦子, 澤田杏理, 竹内和博, 畑中彩恵子, 寺崎美佳, 功刀しのぶ, 寺崎泰弘, 松島綱治, 寺島裕也, 清水章

    第112回日本病理学会総会  2023年4月 

     詳細を見る

  • マクロファージ制御の鍵を握る相互作用の発見:がんと炎症性疾患を治療する新たな道 招待

    遠田悦子

    第13回 Top Runners in TRS(東京大学 AMED iD3 キャタリストユニット主催)  2023年11月 

     詳細を見る

    会議種別:公開講演,セミナー,チュートリアル,講習,講義等  

    researchmap

▼全件表示

産業財産権

  • がん又は炎症性疾患患者の予後を予測する方法

    寺島 裕也, 松島 綱治, 遠田 悦子, 大辻 幹哉, 板倉 明司

     詳細を見る

    出願人:国立大学法人 東京大学, 千葉県

    出願番号:JP2016050555  出願日:2016年1月

    公開番号:WO2016-111364  公開日:2016年7月

    J-GLOBAL

    researchmap

  • がん微小環境又は炎症性微小環境の構成細胞の制御剤

    寺島 裕也, 松島 綱治, 遠田 悦子, 寺沢 宏明, 吉永 壮佐

     詳細を見る

    出願人:国立大学法人 東京大学

    出願番号:JP2016050214  出願日:2016年1月

    公開番号:WO2016-111307  公開日:2016年7月

    J-GLOBAL

    researchmap

受賞

  • 日本医科大学賞(研究部門)

    2024年3月  

     詳細を見る

  • 研究助成金

    2022年   公益財団法人ライフサイエンス振興財団  

     詳細を見る

  • ノバルティス研究奨励金

    2022年   公益財団法人ノバルティス科学振興財団  

     詳細を見る

  • 第48回日本免疫学会学術集会ベストプレゼンテーション賞

    2019年12月   A chemokine signal amplifier FROUNT regulates tumor cell-mediated macrophage activation and migration to tumor sites

     詳細を見る

  • 第18回分子予防環境医学研究会若手優秀発表賞

    2019年1月   ケモカイン受容体シグナル促進分子FROUNT(フロント)の 炎症性病態調節因子としての可能性

    遠田悦子

     詳細を見る

  • 第47回日本免疫学会学術集会ベストプレゼンテーション賞

    2018年12月   A chemokine signal amplifier FROUNT promotes tumor progression by facilitating migration and activation of tumor-associated macrophage

    遠田悦子

     詳細を見る

  • The Naito Foundation Poster Award

    2018年6月   Blocking tumor-promoting macrophages by interrupting the interaction of chemokine receptors and a cytoplasmic regulatory protein FROUNT

    遠田悦子

     詳細を見る

  • The Young Investigator Award

    2015年7月   The International Conference of Cancer Immunotherapy and Macrophages 2015

    遠田悦子

     詳細を見る

▼全件表示

共同研究・競争的資金等の研究課題

  • 人工知能を用いた術前子宮体癌検出のための新規病理診断サポートモデルの開発

    研究課題/領域番号:23K08900  2023年4月 - 2026年3月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    寺崎 美佳, 遠田 悦子, 高熊 将一朗, 寺崎 泰弘

      詳細を見る

    配分額:4680000円 ( 直接経費:3600000円 、 間接経費:1080000円 )

    researchmap

  • FROUNTを標的とした特発性間質性肺炎治療薬の治験準備

    2023年4月 - 2026年3月

    国立研究開発法人日本医療研究開発機構(AMED)  難治性疾患実用化研究事業 

      詳細を見る

    担当区分:研究分担者 

    researchmap

  • 炎症病態のカギを握る単球の遊走・活性化促進分子FROUNTを標的とした炎症免疫応答正常化

    2022年4月 - 2023年3月

    公益財団法人ライフサイエンス振興財団  研究助成金 

      詳細を見る

    担当区分:研究代表者 

    researchmap

  • マクロファージの「動き」と「活性化」の相互連関メカニズム

    2022年4月 - 2023年3月

    公益財団法人ノバルティス科学振興財団  ノバルティス研究奨励金 

      詳細を見る

  • 難治性胃がんを対象とした新規FROUNT特異的阻害薬の開発研究

    研究課題/領域番号:21444555  2021年10月 - 2024年3月

    国立研究開発法人日本医療研究開発機構(AMED)  革新的がん医療実用化研究事業 

      詳細を見る

    担当区分:研究分担者 

    researchmap

  • フロント阻害薬ジスルフィラムによるマクロファージ阻害を介した糖尿病腎線維化の抑制

    研究課題/領域番号:21K08240  2021年4月 - 2024年3月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    遠藤 陽子, 清水 章, 遠田 悦子, 中村 元信

      詳細を見る

    配分額:4030000円 ( 直接経費:3100000円 、 間接経費:930000円 )

    Disulfiram (DSF)による糖尿病性腎臓病(DKD)、間質線維化・尿細管萎縮(IFTA)抑制効果を確認するため、Spargue Dawleyラットにstreptozotocinを投与し、血糖・尿糖により糖尿病発症を確認した。発症後1か月毎に腎組織でIFTA、動脈硬化、マクロファージ浸潤を免疫染色も行い評価し、Streptozotocin非投与群と7か月目まで比較を行い、DKDやIFTAが進行していることを確認した。糖尿病発症後、1か月目にDSF投与を開始し、同様に組織学的評価を行い、非糖尿病群・糖尿病群(無治療)・糖尿病群(DSF)と比較検討を行った。IFTAについても組織学的評価を実施中である。また発症前、発症後1か月毎の血液・尿を採取し、IFTAのマーカーとなり得る既存因子(尿細管障害のマーカー)や、尿中アルブミン濃度の評価を実施した。

    researchmap

  • ケモカイン受容体会合分子による白血球遊走におけるPI3K活性化機構の解明と応用

    研究課題/領域番号:21H02755  2021年4月 - 2024年3月

    日本学術振興会  科学研究費助成事業  基盤研究(B)

    寺島 裕也, 松島 綱治, 遠田 悦子

      詳細を見る

    配分額:17290000円 ( 直接経費:13300000円 、 間接経費:3990000円 )

    researchmap

  • COVID-19に対する抗ウイルス/抗炎症デュアル制御剤の非臨床開発

    2021年3月 - 2022年3月

    国立研究開発法人日本医療研究開発機構(AMED)  新興・再興感染症に対する革新的医薬品等開発推進研究事業 

      詳細を見る

    担当区分:研究分担者 

    researchmap

  • 多様なリンパ球増殖性肺病変の局所リンパ球のプロファイリングとバイオマーカー開発

    研究課題/領域番号:20K08553  2020年4月 - 2023年3月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    寺崎 泰弘, 寺崎 美佳, 遠田 悦子, 康 徳東

      詳細を見る

    配分額:4420000円 ( 直接経費:3400000円 、 間接経費:1020000円 )

    Crystal storing histiosytosis(CSH)合併MALT例において結晶は組織球・形質細胞の細胞内のみに存在した。一方Crystalglobulinemia syndrome(CGS)合併MM例において結晶は肺組織球内と肺胞腔、腎尿細管腔などの細胞外にのみ存在し、骨髄の形質細胞内や周囲細胞外には見られなかった。対照として施行した、“結晶のない多発性骨髄腫MM5例”では骨髄形質細胞の内・外には結晶は認められなかった。
    結晶およびそのソースである形質細胞をレーザーマイクロダイセクションで、ピンポントでサンプリングを行い、LCMS/MS解析した。CSH合併MALT例では形質細胞から低頻度のκ-V region ((Spectra:0)とIgM (1)が検出されたが、結晶からは高頻度spectra(9)のκ-V region が検出された。CGS合併MM例では、骨髄形質細胞から低頻度のλ-2 C region (2)と IgG-1 C regionが検出されたが、結晶からは高頻度のλ-2 C region (20)とIgG-1 C region(6)が検出された。対照とした“結晶のないMM5例”の形質細胞からは少~中頻度のIgAやκが検出されたのみであった。形質細胞から検出されたImmunoglobulinのspectraは低頻度であったが、結晶からは高頻度の検出がなされた。CSH合併MALT例では組織球・形質細胞の細胞内のみに存在しており、異常増殖したImmunoglobulin が細胞内でのみ結晶化していると考えられた。CGS合併MM例では肺組織球内と肺胞腔、腎尿細管腔の細胞外にのみ見られ、骨髄細胞内・外では認められなかった事から、異型形質細胞から過剰分泌されたImmunoglobulin が肺胞腔内や尿細管腔の細胞外で結晶化した可能性が考えられた。

    researchmap

  • 子宮肉腫におけるターゲット因子抑制とその応用

    研究課題/領域番号:20K09680  2020年4月 - 2023年3月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    寺崎 美佳, 遠田 悦子, 寺崎 泰弘

      詳細を見る

    配分額:4420000円 ( 直接経費:3400000円 、 間接経費:1020000円 )

    子宮平滑筋肉腫は多彩な組織像を示すが、形態の違いに基づく治療選択は行われておらず、治療に直結する有効な治療法の開発が急務となっている。私たちは、破骨細胞型巨細胞を伴う子宮平滑筋肉腫では、骨の破骨細胞形成に必須のサイトカイン(RANKL)を産生していることを発見し、組織形態の違いが腫瘍の発生起源に関わる可能性を解明し、治療ターゲットとなり得る因子を同定することを目的に研究を行った。RANKLの上流因子に関しては、過去に報告されているRANKL誘導作用があるサイトカイン群の関わりは薄い結果であった。しかし腫瘍組織において、RANKL以外に、オステオポンチンの高発現を有意に認めたことから、発想を転換し、骨芽細胞分化について検討を進めたところ、腫瘍細胞に骨芽細胞化を誘導する転写因子RUNX2の高発現を認めた。
    RUNX2は近年前立腺癌や腎癌、肺癌において予後不良因子としての報告がみられる。RUNX2とRANKLの発現局在の検討から、腫瘍細胞の多くはRUNX2を発現し、その一部がRANKLを発現していることが明らかとなった。また腫瘍内マクロファージおよび破骨型巨細胞では、RANKL受容体や破骨細胞分化に必須の転写因子の発現がみられ、骨吸収に関与するコラーゲン分解酵素であるCathepsin Kの強発現がみられた。このことから、破骨細胞様巨細胞を伴う子宮平滑筋肉腫では、腫瘍細胞の骨芽細胞化により、RANKL-RANKシグナルにより腫瘍内のマクロファージが骨組織と同様の機序で破骨細胞化することで、特徴的な組織像を示している可能性が示唆された。また組織球の破骨細胞化は、周囲間質のIV型コラーゲン分解を促進し、出血を引き起こす事で、易転移性を示す可能性が考えられた。上記結果と考察を論文にまとめ、英文紙に投稿し、採択された(Virchows Archiv, 2021)。

    researchmap

  • 疾患病態を反映するマクロファージの免疫形態学的指標の探索

    研究課題/領域番号:20K07553  2020年4月 - 2023年3月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    遠田 悦子, 寺島 裕也

      詳細を見る

    配分額:4420000円 ( 直接経費:3400000円 、 間接経費:1020000円 )

    マクロファージはケモカインなどの遊走因子の刺激を受けて炎症・傷害組織に浸潤し、微小環境に応じて多様な性質を獲得して炎症・免疫応答の中核を担っている。ケモカイン受容体会合分子FROUNTはマクロファージの細胞遊走を促進し、がんや炎症性疾患の増悪化に関与するとともに、欠損あるいは阻害により特有の形態を示す。本研究ではマクロファージの機能と形態との相関を明らかにし、形態的特徴からマクロファージの機能や病態との関わりを推測する手法を探索することを目的とする。本年度は、ラットおよびマウスの骨髄細胞から骨髄由来マクロファージを調製し、各種刺激(CCL2、LPS、IL-4等)によって誘導される細胞形態変化を光学顕微鏡観察、重合アクチン染色による細胞骨格の可視化により観察した。さらに細胞表面の微細な形態変化を観察するため、低真空走査電子顕微鏡を用いて微細観察する条件を検討した。これらの手法を用いて観察することにより、各種刺激により誘導される形態の違いを明らかにした。これらの細胞形態の変化に対応する遺伝子発現の変化を捉えるため、各種刺激後の異なるタイムポイントでマクロファージからトータルRNAを抽出し、遺伝子発現解析を行った。さらにケモカイン受容体会合分子FROUNTの欠損マウス由来の骨髄由来マクロファージや、FROUNT阻害剤を用いて、各種刺激後の細胞の形態変化および遺伝子発現の変化におけるFROUNT欠損や阻害の影響を評価した。細胞間のばらつきを抑えて、刺激の違いや遺伝子欠損による形態変化の違いを抽出するために、均一な形態変化を捉えるための条件を現在検討中である。

    researchmap

  • マクロファージの獲得免疫制御におけるケモカイン受容体会合分子FROUNTの役割

    研究課題/領域番号:17K15716  2017年4月 - 2022年3月

    日本学術振興会  科学研究費助成事業  若手研究(B)

    遠田 悦子

      詳細を見る

    配分額:4290000円 ( 直接経費:3300000円 、 間接経費:990000円 )

    ケモカイン受容体細胞内会合分子FROUNT(フロント)は、マクロファージの遊走・集積に促進的に働く。炎症性疾患においては、マクロファージの活性化状態は適応免疫応答にも影響を与える。本研究では、マクロファージによる適応免疫応答制御におけるFROUNTの役割の解明を目的とする。本年度は、昨年度までに誘導条件をセットアップしたFROUNT欠損マクロファージを用いて、各種刺激に対する応答性を解析した。刺激後のマクロファージの応答性の解析を容易にするために、温度応答性細胞培養プレートを用いた。骨髄細胞より分化誘導したコントロールおよびFROUNT欠損マクロファージにLPS刺激を行い、刺激後のマクロファージを回収してフローサイトメトリーにより細胞表面活性化マーカーの解析を行った結果、刺激後にCD80、CD86、MHC class IIなどの活性化マーカーの発現増強が認められ、これについてフロント欠損マクロファージでは刺激後の発現増強の減弱が認められた。また、通常の培養プレート内で刺激を行った際にはマクロファージの接着能亢進が認められたが、これがFROUNT欠損により減弱することを示唆する結果を得た。T細胞とマクロファージの共培養系において、サイトカイン・抗サイトカイン抗体添加による各ヘルパーT細胞サブセット誘導条件で共存するマクロファージにおけるFROUNT欠損の影響を解析した結果、FROUNT欠損による各ヘルパーT細胞サブセット誘導効率の違いは認められなかった。今後はIn vivoの病態モデルで認められているT細胞サブセットの変化について、さらなる検討を進める。

    researchmap

  • 新規ケモカイン受容体会合分子フロントによる慢性炎症性疾患の分子制御

    研究課題/領域番号:26860317  2014年4月 - 2017年3月

    日本学術振興会  科学研究費助成事業  若手研究(B)

    遠田 悦子, 寺島 裕也, 南木 敏宏

      詳細を見る

    配分額:3900000円 ( 直接経費:3000000円 、 間接経費:900000円 )

    関節リウマチなどの慢性炎症性疾患においては、ケモカインを介した白血球の過剰な集積・浸潤が病態形成に密接に関与している。本研究ではケモカインシグナル促進分子FROUNT(フロント)の関節リウマチにおける役割について解析を行った。FROUNTを欠損したマウスでは関節リウマチの発症および重症化が改善され、免疫誘導期および炎症期の双方への関与が示唆された。またマクロファージの減少と、T細胞サブセットにおけるTregの増加およびTh17の減少が認められ、関節炎に関連する免疫応答が減弱することが明らかになった。以上より、FROUNTは関節炎発症および重症化に重要な役割を担っていることが示された。

    researchmap

  • ケモカイン受容体会合分子による免疫制御機構の解析

    研究課題/領域番号:12J40099  2012年

    日本学術振興会  科学研究費助成事業 特別研究員奨励費  特別研究員奨励費

    遠田 悦子

      詳細を見る

    配分額:2400000円 ( 直接経費:2400000円 )

    ケモカイン受容体シグナル制御分子フロントは、ケモカイン受容体CCR2に結合し炎症反応において重要な働きを担うマクロファージの炎症の場への遊走を正に制御する。本研究では、フロント遺伝子改変マウスおよびフロント機能制御化合物を用いて、炎症時における生体レベルでのフロントの機能および細胞内遊走シグナル関連分子の活性化制御機構を明らかにすることを目的とする。
    平成24年度までに同定したCCR2上のフロント結合領域について細胞レベルでの機能解析を行った。まずフロントとの結合を低下させる1アミノ酸変異を導入した変異型CCR2を培養細胞に発現させた。この変異は、in vitroで明らかとなったフロントとの結合エレメントである結合領域ヘリックスの疎水性面に位置する。細胞表面上の発現レベルは野生型と同程度であった。CCR2の受容体機能である細胞遊走活性に対するこの変異の影響を解析するため、Boyden chamber法にて変異型CCR2発現細胞のCCR2リガンド(CCL2)刺激に対する遊走活性を解析した。その結果、変異型CCR2を発現する細胞においては、野生型CCR2を発現する細胞に比べて遊走活性が顕著に低下していた。これよりin vitroの解析で明らかになったCCR2上のフロント結合エレメントは、細胞レベルにおいても受容体の機能に重要な役割を担っていることが示された。またフロント遺伝子改変マウスの炎症モデルにおける表現型解析およびフロント機能阻害化合物の炎症モデルでの抗炎症効果の解析を行うため、コラーゲン誘導性関節炎モデルのセットアップを行い、DBA/1I係統における関節炎モデルでのフロント機能阻害化合物の評価が可能となった。

    researchmap

▼全件表示

担当経験のある授業科目

  • 免疫学(東京農業大学)

    2022年
    -
    現在

     詳細を見る

  • 人体形態学論:病理学

    2022年
    -
    現在
    機関名:東京医療福祉専門学校

     詳細を見る

  • 病理学概論

    2022年
    -
    現在
    機関名:東京医療学院

     詳細を見る

  • 免疫病理(日本医科大学)

    2021年
    -
    現在

     詳細を見る